Cerebral oxygenation is stable in preterm infants transitioning to heated humidified high‐flow nasal cannula therapy

Sett, Arun; Noble, Elizabeth; Forster, Danielle Elizabeth; Collins, C

doi:10.1111/apa.15811

Cited by 2 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[41][42][43][44][45] Additionally, the physiological effects achieved during HFNC and NCPAP treatment are similar, including SpO 2 , heart rate (HR), and FiO 2. [90][91]…”

Section: Recommendation 3: Hfnc Can Be Used As An Alternative To Ncpa...mentioning

confidence: 99%

“…Additionally, the physiological effects achieved during HFNC and NCPAP treatment are similar, including SpO 2 , heart rate (HR), and FiO 2. 90–91 This suggests that it reduces upper airway and alveolar collapse, increases functional residual capacity, and reduces WOB through the low positive airway pressure generated by HFNC, thereby improving oxygenation and reducing the occurrence of bradycardia. For the treatment of AOP, HFNC had similar efficacy when compared with NCPAP.…”

Section: Key Questions Recommendations Evidence Summary and Recommend...mentioning

confidence: 99%

See 1 more Smart Citation

Guidelines for high‐flow nasal cannula oxygen therapy in neonates (2022)

Huang,

Zhao,

Hua

et al. 2023

J Evidence Based Medicine

View full text Add to dashboard Cite

High‐flow nasal cannula (HFNC) oxygen therapy, which is important in noninvasive respiratory support, is increasingly being used in critically ill neonates with respiratory failure because it is comfortable, easy to setup, and has a low incidence of nasal trauma. The advantages, indications, and risks of HFNC have been the focus of research in recent years, resulting in the development of the application. Based on current evidence, we developed guidelines for HFNC in neonates using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). The guidelines were formulated after extensive consultations with neonatologists, respiratory therapists, nurse specialists, and evidence‐based medicine experts. We have proposed 24 recommendations for 9 key questions. The guidelines aim to be a source of evidence and reference of HFNC oxygen therapy in clinical practice, and so that more neonates and their families will benefit from HFNC.

show abstract

“…[41][42][43][44][45] Additionally, the physiological effects achieved during HFNC and NCPAP treatment are similar, including SpO 2 , heart rate (HR), and FiO 2. [90][91]…”

Section: Recommendation 3: Hfnc Can Be Used As An Alternative To Ncpa...mentioning

confidence: 99%

Section: Key Questions Recommendations Evidence Summary and Recommend...mentioning

confidence: 99%

Guidelines for high‐flow nasal cannula oxygen therapy in neonates (2022)

Huang,

Zhao,

Hua

et al. 2023

J Evidence Based Medicine

View full text Add to dashboard Cite

show abstract

Feasibility and safety of weaning premature infants from nasal continuous positive airway pressure to high-flow nasal cannula: a prospective observational case study

Yang,

Chung,

Chen

2024

BMC Pediatr

View full text Add to dashboard Cite

Background Nasal continuous positive airway pressure (NCPAP) is widely used for premature infants with respiratory distress syndrome (RDS). A high-flow nasal cannula (HFNC) provides positive end-expiratory pressure using high-flow oxygen; however, the variability in distending pressure is a primary concern. This study evaluated the feasibility and safety of a newly designed protocol for NCPAP weaning with cyclic HFNC use for premature infants. Methods Premature infants with RDS using NCPAP support who were ready for weaning were enrolled. The weaning protocol used cyclic NCPAP with HFNC every 3 h for 3 days in the neonatal intensive care unit. The heart rate (HR), respiratory rate (RR), pulse oximetry (SpO2), transcutaneous carbon dioxide (PtcCO2), and cerebral tissue oxygen saturation (StO2) at the end of NCPAP with HFNC support were recorded once daily for 3 days. Results From June 2019 to April 2021, 46 premature infants (27 male, 19 female) were enrolled. The mean gestational age and birth body weight were 28.7 ± 2.6 weeks and 1181 ± 354 g, respectively. No statistically significant differences in the HR, RR, SpO2, and cerebral StO2 during NCPAP weaning with HFNC were observed. However, the mean PtcCO2 with NCPAP was statistically significantly lower than that with HFNC (46.9 ± 6.0 mmHg vs. 47.9 ± 6.4 mmHg, P = 0.02). Conclusions The feasibility and safety of the NCPAP weaning protocol with cyclic HFNC for premature infants are acceptable in this preliminary study. Due to the limited number of participants, further studies are required for more comprehensive analysis. Trial registration This prospective observational case study was approved by the Human Experiment and Ethics Committee of our hospital (approval number: KMUHIRB-SV(I)-20180059; approval date: January 11, 2019).

show abstract

Cerebral oxygenation is stable in preterm infants transitioning to heated humidified high‐flow nasal cannula therapy

Cited by 2 publications

References 31 publications

Guidelines for high‐flow nasal cannula oxygen therapy in neonates (2022)

Guidelines for high‐flow nasal cannula oxygen therapy in neonates (2022)

Feasibility and safety of weaning premature infants from nasal continuous positive airway pressure to high-flow nasal cannula: a prospective observational case study

Contact Info

Product

Resources

About